Does it matter that much that MT is leaving in 4 months with ODD decision and phase 2/3 study beginning before he leaves. Won't be a lot to do for 6 months other than report interim results and wait for midway point of study.
All participants are now taking 10mg/kg/day as cohort 2 did in below phase 1 trial. CSF NfL level reduced markedly more in cohort 2 compared to cohort 1 (granted only 3 participants measured). ALS function rating score slower decline at higher dose.
RvR too good to ignore for this stock.
Ann: Resignation of Dr Michael Thurn & appointment of John Clark, page-121
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $94.79M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 19.5¢ | $188.9K | 946.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 800531 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 49199 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |